UroGen Pharma (URGN) Net Equity Issued and Repurchased (2017 - 2025)

UroGen Pharma (URGN) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $31.8 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $31.8 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $40.0 million (down 57.9% YoY) and the FY2025 annual result came in at $39.8 million, down 73.67% from the prior year.
• Net Equity Issued and Repurchased climbed to $31.8 million in Q4 2025, from $8.2 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $80.1 million in Q2 2024 to a low of -$4000.0 in Q2 2025.
• A 3-year average of $32.3 million and a median of $23.4 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 45.34% in 2025, down 100.0% in 2025.
• Tracing URGN's Net Equity Issued and Repurchased over 3 years: stood at $67.4 million in 2023, then plunged by 77.73% to $15.0 million in 2024, then surged by 112.16% to $31.8 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $31.8 million (Q4 2025), $8.2 million (Q3 2025), and -$4000.0 (Q2 2025), per Business Quant data.